Genomic Analysis of Anti-Hepatitis B Virus (HBV) Activity by Small Interfering RNA and Lamivudine in Stable HBV-Producing Cells
Open Access
- 15 November 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (22), 14392-14403
- https://doi.org/10.1128/jvi.79.22.14392-14403.2005
Abstract
Hepatitis B virus (HBV) causes acute and chronic hepatitis and hepatocellular carcinoma. Small interfering RNA (siRNA) and lamivudine have been shown to have anti-HBV effects through different mechanisms. However, assessment of the genome-wide effects of siRNA and lamivudine on HBV-producing cell lines has not been reported, which may provide a clue to interrogate the HBV-cell interaction and to evaluate the siRNA's side effect as a potential drug. In the present study, we designed seven siRNAs based on the conserved HBV sequences and tested their effects on the expression of HBV genes following sorting of siRNA-positive cells. Among these seven siRNAs, siRNA-1 and siRNA-7 were found to effectively suppress HBV gene expression. We further addressed the global gene expression changes in stable HBV-producing cells induced by siRNA-1 and siRNA-7 by use of human genome-wide oligonucleotide microarrays. Data from the gene expression profiling indicated that siRNA-1 and siRNA-7 altered the expression of 54 and 499 genes, respectively, in HepG2.2.15 cells, which revealed that different siRNAs had various patterns of gene expression profiles and suggested a complicated influence of siRNAs on host cells. We further observed that 18 of these genes were suppressed by both siRNA-1 and siRNA-7. Interestingly, seven of these genes were originally activated by HBV, which suggested that these seven genes might be involved in the HBV-host cell interaction. Finally, we have compared the effects of siRNA and lamivudine on HBV and host cells, which revealed that siRNA is more effective at inhibiting HBV expression at the mRNA and protein level in vitro, and the gene expression profile of HepG2.2.15 cells treated by lamivudine is totally different from that seen with siRNA.Keywords
This publication has 48 references indexed in Scilit:
- Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatmentVirus Research, 2005
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- siRNAs: applications in functional genomics and potential as therapeuticsNature Reviews Drug Discovery, 2004
- Inhibition of HBV replication by siRNA in a stable HBV-producing cell lineHepatology, 2003
- Induction of an interferon response by RNAi vectors in mammalian cellsNature Genetics, 2003
- Expression profiling reveals off-target gene regulation by RNAiNature Biotechnology, 2003
- RNA interferenceNature, 2002
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- A general method applicable to the search for similarities in the amino acid sequence of two proteinsJournal of Molecular Biology, 1970